JCM
ACAD icon

Jacobi Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Jacobi Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed – – 434
2021
Q3 		$0 Hold
20
– – ﹤0.01% 1432
2021
Q2 		$0 Buy
+20
New +$451 ﹤0.01% 1376

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Jacobi Capital Management's ACAD Position: Q4 2021 in Review

Jacobi Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 20 shares.

Jacobi Capital Management first reported a position in ACAD in Q2 2021 and held it in 2 quarters. The position peaked at $0 in Q3 2021. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

  • Jacobi Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 20 Acadia Pharmaceuticals shares in Q4 2021.
  • Jacobi Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Jacobi Capital Management's Acadia Pharmaceuticals position peaked at $0 in Q3 2021.
  • 247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.